The past couple of years have been challenging for the company. But this could be the beginning of a new chapter.

Danish drugmaker Novo Nordisk and Canada-based privately held Aspect Biosystems said on Tuesday they have struck a ...

Why economic leverage beats military pressure on Greenland, and how Denmark’s exposure through Novo Nordisk makes trade tools ...

Shares in Denmark's global healthcare company, Novo Nordisk jumped sharply on Friday after the U.K.'s regulator signed off on ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects healthy upside for Novo Nordisk stock through ...

Aspect will acquire rights from Novo Nordisk to stem cell-derived islet cell and hypoimmune cell engineering technologies.

Novo Nordisk entered 2026 with fresh momentum after the U.S. launch of its oral Wegovy pill. Is the stock a buy now?

Novo Nordisk has found a buyer for cell therapy technologies dropped in its retreat from the modality. Aspect Biosystems has ...

Partnership evolution includes strategic integration of select Novo Nordisk technologies into Aspect BiosystemsAspect will ...

The iShares MSCI Denmark ETF is rated a buy, supported by Denmark’s strong fundamentals and macroeconomic tailwinds. Learn ...

The Novo Nordisk Foundation has allocated up to DKK 5.5 billion (EUR 736 million) to BioInnovation Institute (BII), a leading ...

Novo Nordisk's Wegovy weight-loss pill has made an "encouraging" start after its launch this month, analysts said on Friday ...